Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243524 · ClinicalTrials.gov registry record · Phase 2
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
A Phase 2 study, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05243524 is a Phase 2 study that was terminated before completion, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 16 participants.
The verdict
NCT05243524, a Phase 2 study, was terminated before completion, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
Interventions
- DRUG Cyclophosphamide 50mg
- OTHER Maveropepimut-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243524
The ClinicalTrials.gov registry entry for NCT05243524 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide 50mg is the first listed.
NCT05243524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05243524 about?
NCT05243524 is a clinical study titled "Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer". Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
What is the current status of trial NCT05243524?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-08-05. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05243524?
The interventions under investigation include: Cyclophosphamide 50mg (DRUG), Maveropepimut-S (OTHER).
Who is sponsoring clinical trial NCT05243524?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.